Ningbo Rongyu

Ningbo Rongyu Biotechnology is a clinical-stage biopharmaceutical company headquartered in Ningbo, China, specializing in the development of next-generation small molecule drugs. The company's primary focus lies in metabolic disorders and oncology, utilizing a proprietary technology platform to design oral therapies with improved bioavailability and efficacy. Its lead candidate, RY001, is an orally administered small molecule GLP-1 receptor agonist currently undergoing clinical trials for the treatment of obesity and type 2 diabetes. Supported by leading venture capital firms such as HighLight Capital and Qiming Venture Partners, Ningbo Rongyu aims to provide more accessible and convenient treatment options for chronic metabolic conditions. The firm continues to expand its pipeline with early-stage programs targeting high-value oncology and metabolic pathways.